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The relationships between diabetes and pancreatic
ductal adenocarcinoma (PDAC) are complex. Long-
standing type 2 diabetes (T2DM) is a risk factor for
pancreatic cancer, but increasing epidemiological
data point to PDAC as also a cause of diabetes due to
unknown mechanisms. New-onset diabetes is of partic-
ular interest to the oncology community as the differen-
tiation of new-onset diabetes caused by PDAC as distinct
from T2DM may allow for earlier diagnosis of PDAC. To
address these relationships and raise awareness of the
relationships between PDAC and diabetes, a symposium
entitled Diabetes, Pancreatogenic Diabetes, and Pancre-
atic Cancer was held at the American Diabetes Associ-
ation’s 76th Scientiﬁc Sessions in June 2016. This article
summarizes the data presented at that symposium, de-
scribing the current understanding of the interrelation-
ships between diabetes, diabetes management, and
pancreatic cancer, and identiﬁes areas where addi-
tional research is needed.
The most common and most lethal form of pancreatic
cancer, referred to as pancreatic ductal adenocarcinoma
(PDAC), has an extraordinary association with diabetes.
In a recent series of 100 patients diagnosed with cancers
of the lung, breast, colon, prostate, or pancreas, 68% of
patients with PDAC had concurrent diabetes, whereas the
prevalence of diabetes ranged from 15 to 21% in the other
age-matched cancer cohorts and 24% in 100 age-matched
control subjects (1). The increased incidence of pancreatic
cancer in populations with diabetes has been observed
repeatedly in epidemiological studies, with a relative risk
or hazard ratio that ranges from 1.5 to 2.0 (2). Impor-
tantly, among patients with PDAC who also have diabetes,
the diagnosis of diabetes occurred less than 24 months
prior to the diagnosis of PDAC in 74–88% of patients (3).
These facts illustrate that diabetes and PDAC demon-
strate “dual causality,” in that both long-standing type
2 diabetes (T2DM) is a risk factor for the development
of PDAC and, conversely, PDAC is a presumed cause of
diabetes in a large number of cases. The mechanisms of
these causal relationships are unclear, as are the diagnos-
tic criteria for differentiating T2DM from diabetes that
occurs as an early consequence of PDAC. These are im-
portant considerations clinically given that PDAC has an
overall 5-year survival rate of 7–8% (4) and that it is
projected to become the second leading cause of cancer-
related deaths by 2020 (5). To explore these issues, a
symposium was held at the 76th Scientiﬁc Sessions of
the American Diabetes Association in 2016. The following
represents a summary of the symposium presentations,
with the purpose of providing more insight into these
important relationships.
DIABETES AS A RISK FACTOR FOR PDAC
The Centers for Disease Control and Prevention estimates
that approximately 29 million people in the U.S. had
1Division of Digestive Diseases and Nutrition, National Institute of Diabetes and
Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD
2Division of Endocrinology, Department of Medicine, and Department of Bio-
chemistry and Molecular Biology, Indiana University School of Medicine, and
Indiana University Melvin and Bren Simon Cancer Center and Pancreatic Cancer
Signature Center, Indianapolis, IN
3Department of Health Sciences Research, Mayo Clinic, Rochester, MN
4Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA
5Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center,
Houston, TX
6Division of Endocrinology, Diabetes and Metabolism, Department of Medicine,
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
7Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic,
Rochester, MN
8Division of Medical Oncology, Department of Medicine, Duke University School of
Medicine, Durham, NC
Corresponding author: James L. Abbruzzese, james.abbruzzese@duke.edu.
Received 30 November 2016 and accepted 25 January 2017.
© 2017 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt, and the
work is not altered. More information is available at http://www.diabetesjournals
.org/content/license.
Diabetes Volume 66, May 2017 1103
P
E
R
S
P
E
C
T
IV
E
S
IN
D
IA
B
E
T
E
S
T2DM in 2014, and about 8 million of these individuals
have not yet been diagnosed. Moreover, approximately
86 million adults in the U.S. are believed to have
prediabetes, deﬁned by a fasting plasma glucose level
of 100–125 mg/dL, a 2-h plasma glucose level of
140–199 mg/dL, or a glycohemoglobin (HbA1c) level of
5.7–6.4% (6). These statistics put into perspective the
difﬁculties inherent in using glucose intolerance and
diabetes as biomarkers for diagnosing PDAC-associated
diabetes. The global spread of this huge health care bur-
den further underscores the need to better understand
the pathophysiology of T2DM and to distinguish it from
pancreatogenic or type 3c diabetes (T3cDM), which has
been classiﬁed as diabetes secondary to pancreatic exo-
crine disease.
Long-standing T2DM is a risk factor for PDAC (7).
In addition, T2DM is often associated with obesity, and
obesity per se also increases the risk for developing
PDAC (8). T2DM is associated with resistance to the ac-
tion of insulin to suppress hepatic glucose release. Con-
comitantly, there is failure to enhance peripheral
(predominantly skeletal muscle) glucose utilization, with
initially increased insulin levels, as the b-cell attempts to
overcome the insulin resistance (9). With time, there is
progressive b-cell failure leading to T2DM including
aberrant activation of the unfolded protein response
pathway, which may induce both apoptosis and senes-
cence leading to a decreased b-cell mass (10). Neverthe-
less, both obesity and T2DM are likely to lead to long time
periods in which such individuals have high intrapancre-
atic insulin levels due to an ongoing impetus by the b-cell
to overcome the insulin-resistant state and maintain glu-
cose homeostasis.
Insulin released by the b-cells is discharged into an
intrapancreatic portal circulation that provides blood to
acinar and ductal cells adjacent to the islets. Both cell
types can be adjacent to the islets and may be supplied
by blood from the intrapancreatic portal circulation (Fig. 1).
This proximity enables high levels of islet hormones to
directly reach groups of acinar and ductal cells, exerting
what has been termed proxicrine effects on insulin recep-
tors that are present on acinar cells and on IGF-I recep-
tors in any transformed cells that may arise in this region,
thereby promoting their survival and proliferation. Thus,
hyperinsulinemia, particularly intrapancreatic, as a result
of obesity and insulin resistance in prediabetes or early
T2DM may plausibly contribute to the observed increased
risk in PDAC.
Additionally, poor glycemic control is associated with
increased levels of advanced glycation end products (AGE)
that activate a receptor for AGE termed RAGE (11). This
receptor belongs to the immunoglobulin super family and
binds several ligands in addition to AGE, including certain
inﬂammatory cytokines and members of the S100 family
of proteins that have been implicated in inﬂammation
and cancer, including PDAC (11). Moreover, RAGE activa-
tion contributes to the development of obesity and its
associated proinﬂammatory proﬁle (12). Conceivably,
therefore, excessive RAGE activation may also contribute
to the higher incidence of PDAC in T2DM, as well as to
the increased incidence of colorectal cancer, breast cancer,
and other cancers that may occur with T2DM and obesity.
GENOMIC ASSOCIATIONS OF DIABETES,
CHRONIC PANCREATITIS, AND PANCREATIC
CANCER
Although there is strong clinical and epidemiological
evidence that links the risk of PDAC to long-standing
T2DM or to chronic pancreatitis (CP) (the most frequent
cause of T3cDM), the genetic basis of susceptibility among
these three diseases varies widely, with little overlap.
Indeed, genetic heterogeneity of all three is the rule.
Through extensive studies of case series and families
and using a variety of study designs, catalogs of genes
have been identiﬁed for each condition. Interestingly,
what is known about the mechanism by which these
genes inﬂuence susceptibility is uneven because of the
different methods used to identify the genes.
All three diseases share the following characteristics:
1) all have subsets of patients who report family history or
familial clustering, which are indicators of shared genetic
and/or environmental etiologies, 2) variation in age at di-
agnosis has been linked to familial risk in some patients,
and 3) Mendelian segregation analyses provide a formal
demonstration that in some families there is evidence for
a hereditary component (typically due to a major gene). In
addition, there are epidemiological risk factors (e.g., obesity
Figure 1—Schematic representation of the islet–acinar–ductal axis.
An endocrine islet consisting mostly of insulin-producing b-cells
(green) but also other endocrine cell types such as glucagon (yel-
low) is shown receiving an arterial blood supply (red). Some of this
arterial blood drains into an intrapancreatic (IP) portal circulation
that bathes adjacent acinar and ductal cells. The insulin-rich blood
supply exerts trophic effects on these cells that are most evident in
the acinar cells making up one such acinus. The acinar cells are
large and have many enzyme-rich zymogen granules (shown as
small yellow circles within each acinar cell).
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[diabetes], alcohol intake [CP], and smoking [PDAC]) that
may interact with genetic factors to enhance risk.
Numerous approaches have been used to discover
susceptibility genes, from family-based studies to case-
control and cohort studies that use a small list of candidate
genes; large, agnostic genome-wide association studies
(GWAS) that search for associated single nucleotide poly-
morphisms (SNPs) that are typically noncoding; or
next-generation sequencing. The needed analytic and bio-
informatics methods have kept pace and have provided
the statistical tools for interrogating the resulting data.
The genetic basis of T2DM is best characterized as poly-
genic, with over 50 genes implicated (13). No single major
gene explains the genetic risk of T2DM except in very lim-
ited subsets (14). In contrast, there are well-documented
reports of CP and PDAC kindred that can be delineated as
due to mutations in major genes, while overall GWAS stud-
ies have identiﬁed many low-penetrance common SNPs that
are associated with increased risk.
Among the three conditions, T2DM has been the most
intensively studied, and considerably more resources have
been invested in uncovering the genetics of diabetes,
consistent with the high prevalence and economic burden
of this disease. However, genetic discoveries have not led
to ready clinical application. It is clear from dozens of
studies that diabetes is a multifactorial/polygenic disease
and is genetically heterogeneous. Variants of over 50 genes
have been found to confer genetic risk, each with a modest
effect (e.g., PPARG and KDNJ11, identiﬁed through the
candidate gene approach; and TCF7L2, WFS1, HDF1B,
FTO, CDKN2A, and SLC20A8, among others, identiﬁed
through association and GWAS approaches). Researchers
have developed new strategies in the search for diabetes
predisposition genes by further characterizing the genet-
ic basis of diabetes through subclinical or related pheno-
types (15). The outcome of research to date is that
susceptibility to diabetes ﬁts a polygenic risk model,
with each genetic variant having a small effect. Interest-
ingly, despite these efforts, the genetic variants do not
signiﬁcantly improve risk assessment over common risk
factors such as age, sex, family history, BMI, and clinical
measures (16).
Family-based strategies and knowledge of the path-
ophysiology of CP facilitated early success in elucidat-
ing its genetic heterogeneity and established PRSS1,
SPINK1, CTRC, CFTR, and CASR as susceptibility loci
for CP (17). Much of the variability in susceptibility to
recurrent acute and chronic pancreatitis is related to
genetic differences between patients. A large two-stage
GWAS analysis by Whitcomb et al. (18) identiﬁed and
replicated PRSS1-PRSS2 and X-linked CLDN2 as suscep-
tibility loci, with the latter gene’s variants potentially
interacting with alcohol consumption. Alcohol was long
thought to be the primary causative agent, but genetic
contributions have been of interest since the discovery
that rare PRSS1, CFTR, and SPINK1 variants were associ-
ated with pancreatitis risk. Thus, a single factor rarely
causes pancreatitis, and the majority of patients with re-
current acute and chronic pancreatitis have multiple vari-
ants in a gene, or epistatic interactions between multiple
genes, coupled with environmental stressors.
The study of genetic predisposition to PDAC has been
particularly challenging because of the logistics of recruiting
and collecting biospecimens for analysis from patients with
poor survival. Like diabetes and CP, PDAC is genetically
heterogeneous. Susceptibility genes that have been identiﬁed
range from rare mutations in genes associated with cancer
syndromes to common SNPs. Designs that include family-
based and case-control studies have uncovered mutations
in known syndrome-related genes, such as BRCA1, BRCA2,
CDKN2A, and CFTR. Next-generation sequencing has
identiﬁed additional mutations such as PALB2 (19) and
ATM (20).
More recently, patients with apparent sporadic PDAC
have been reported to carry germline mutations in major
genes as well (21); this is likely to change our current
paradigm for risk assessment. GWAS studies of large
numbers of sporadic cases of pancreatic cancer and con-
trol subjects have implicated SNPs in regions that har-
bor ABO, TERT, and CLPTM1L, among dozens of other
genes. However, risk modeling that utilizes GWAS SNPs
has not shown that the genetic information improves pre-
diction in the general population (22).
THE ROLE OF OBESITY- AND PANCREATITIS-
ASSOCIATED INFLAMMATION IN THE
DEVELOPMENT OF PDAC
There is strong evidence that obesity is associated with an
increased risk of cancer, including pancreatic cancer (23).
In fact, the anticipated increase in pancreatic cancer in-
cidence and deaths may be at least partially attributed to
the obesity endemic. There are many possible mecha-
nisms by which obesity leads to (pancreatic) cancer, in-
cluding insulin resistance with resulting hyperinsulinemia
and inﬂammation (24). Nonsteroidal anti-inﬂammatory
drugs can attenuate pancreatic cancer development in a
genetically engineered mouse model, indicating an impor-
tant role of tissue inﬂammation in this disease (25).
Obesity-associated tissue inﬂammation is thought to create
a fertile microenvironment conducive to tumor initiation
and/or promotion. Recent evidence indicates that in ad-
dition to measures of general obesity, e.g., BMI, visceral
adiposity carries a strong association to metabolic diseases
and gastrointestinal cancers, including pancreatic cancer
(26).
The mesenteric adipose tissue adjacent to the pancreas
(peri-pancreatic depot) showed a substantially enhanced
proinﬂammatory response to a high-fat, high-calorie diet
compared with the peri-gonadal depot (27). A precise
knowledge of adipose tissue depot-speciﬁc responses to
diet-induced obesity and their distinct effects on cancer
development are critically important to explain the asso-
ciation of certain body compositions to cancer risk and to
understand possible sex differences. Mechanistically, a
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high-fat, high-calorie diet accelerates the progression of
pancreatic intraepithelial neoplasia, a known precursor of
pancreatic cancer, and increases the incidence of invasive and
metastatic pancreatic cancer in the conditional KrasG12D
mouse model (28,29).
ANTIDIABETES MEDICATIONS AND THE RISK
OF PDAC
Because various antidiabetes medications can directly
affect the key factors mediating the association between
T2DM and PDAC, some of these medications may have an
impact on PDAC development, progression, and outcome.
High levels of insulin activate the IGF receptor, thereby
acquiring the potential to exert mitogenic and tumor-
promoting effects. Epidemiological studies have found
that new use of insulin was associated with an increased
risk of PDAC (30). Sulfonylureas (insulin secretagogues)
stimulate endogenous release of insulin by inhibiting the
K-ATP channel of the pancreatic b-cells. Use of sulfonyl-
ureas has been associated with an increased risk of pan-
creatic cancer but to a less extent than that for use of
insulin. Thiazolidinediones reduce insulin resistance by
activating peroxisome proliferator–activated receptor g,
a nuclear receptor regulating glucose and lipid metabo-
lism. Use of thiazolidinediones was not associated with
risk of PDAC according to a recent review and meta-
analysis (31).
Incretin-based therapies include glucagon-like pep-
tide 1 (GLP-1) receptor agonists and dipeptidyl pepti-
dase 4 (DPP-4) inhibitors. GLP-1 stimulates insulin secretion
by the b-cell through activation of the GLP-1 receptor
resulting in increased production of cAMP. It also increases
insulin mRNA stability via upregulation of the transcription
factor PDX-1 and, in rodents, promotes b-cell growth and
survival. DPP-4 inhibitors increase the endogenous levels of
GLP-1 and the second principal incretin hormone glucose-
dependent insulinotropic polypeptide (GIP). Therefore,
GLP-1 mimetics and DPP-4 inhibitors may have an indirect
trophic effect on pancreatic ductal cells. The association of
incretin-based therapy and acute pancreatitis has been raised
in clinical studies, and as a result, the U.S. Food and Drug
Administration has issued a warning regarding this relation-
ship. Considering the long latency nature of human malig-
nancies, further studies are required to clarify the association
of incretin use and PDAC.
There is strong experimental evidence to support an
antitumor activity of metformin. The fundamental mech-
anism of metformin action involves two possible avenues:
decreased circulating insulin and IGF levels and inhibition
of mitochondrial oxidative phosphorylation, which conse-
quently leads to energy stress, AMPK activation, and
inhibition of mTOR signaling. A study in 2014 identiﬁed
mitochondrial glycerophosphate dehydrogenase as the ma-
jor molecular target of metformin (32). Inhibition of this
enzyme resulted in an altered hepatocellular redox state,
reduced conversion of lactate and glycerol to glucose, and
decreased hepatic gluconeogenesis.
To date, at least 12 observational studies have investi-
gated the association of metformin use and risk of PDAC
with inconsistent data. A meta-analysis of these studies
showed a summary risk ratio of 0.73 (95% CI 0.56–0.96,
P = 0.023) among metformin users (33). Notably, two ran-
domized clinical trials comparing metformin with active
glucose-lowering therapy or placebo/usual care in T2DM
patients did not ﬁnd any signiﬁcant impact of metformin
use on cancer events. These trials were not designed with
cancer as an end point, and the follow-up times were some-
what short. Even if the protective effect of metformin is
conﬁrmed in future epidemiological studies, more work
needs to be done to identify eligible subpopulations that
would beneﬁt from metformin for PDAC prevention.
Overall, the causal relationship between antidiabetes
therapies and the risk of PDAC cannot be established by
the current observational studies. Many of the reported
observational studies suffered from limitations of in-
sufﬁcient power and inadequate outcome validation,
incomplete covariate ascertainment, and inadequate con-
founding control. Better designed epidemiological inves-
tigations and systematic capture of data on pancreatitis
and PDAC from cardiovascular outcome trials and other
ongoing clinical trials should facilitate meta-analyses and
accumulation of further knowledge.
T3CDM: PREVALENCE, DIFFERENTIATION FROM
T2DM, AND IMPORTANCE OF RECOGNITION
The most common form of T3cDM is diabetes associated
with recurrent acute or chronic pancreatitis, although the
best recognized is cystic ﬁbrosis–related diabetes. Diabe-
tes is also associated with pancreatic cancer, and the most
obvious form of T3cDM is that following partial or com-
plete surgical resection of the pancreas. In recurrent acute
or chronic pancreatitis and in cystic ﬁbrosis, the develop-
ment of exocrine insufﬁciency typically predates the de-
velopment of the endocrine insufﬁciency and diabetes
(34). Any episode of acute pancreatitis can cause a tran-
sient diabetic state and increases the risk of the subse-
quent development of diabetes (35).
The pathophysiology of T3cDM most commonly in-
volves pancreatic glandular inﬂammation and subsequent
irreversible ﬁbrotic damage leading to islet cell loss.
Unlike other types of diabetes, the islet loss involves
not only the b-cells but also the pancreatic polypeptide
(PP) cells early in the disease course and the a-cells late in
the disease course (Table 1). Because of concomitant pan-
creatic exocrine insufﬁciency, there is also maldigestion of
nutrients with consequent impairment in incretin secre-
tion, and pancreatic enzyme replacement can improve
incretin and insulin secretion as well as glucose tolerance.
Typically, islet b-cell secretory capacity is preserved until
the majority of pancreatic exocrine function is lost (36);
however, given how common overweight and obesity are
now in the population, traditional T2DM risk factors and
insulin resistance may accelerate the presentation of di-
abetes in the context of pancreatic disease.
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Importantly, pancreatic disease remains underrecogni-
zed as an underlying etiology of diabetes. At an academic
referral center in Germany, almost 10% of all patients with
diabetes could be classiﬁed as T3cDM, with CP being the
most common etiology affecting 80% of cases (37) (Fig. 2).
In most of these cases, T3cDM was initially misclassiﬁed as
T2DM, leading the authors to propose diagnostic criteria
for T3cDM (38). As outlined in Table 2, the diagnosis of
T3cDM requires 1) the presence of pancreatic exocrine in-
sufﬁciency, 2) evidence of pathological pancreatic imaging,
and 3) the absence of type 1 diabetes (T1DM)-associated
autoimmune markers; the diagnosis may be further sup-
ported by evidence of PP, incretin, or insulin secretory
defects in the absence of clinical or biochemical evidence
of overt insulin resistance. Even with this guidance, discrim-
inating T3cDM secondary to pancreatitis from T2DM can
still be challenging. When ambiguity remains, conﬁrmation
of T3cDM can be made by documentation of an absent PP
response to mixed-nutrient ingestion, which best discrimi-
nates the pathological islet response from that of T2DM (39).
Recognition of T3cDM is important for identiﬁca-
tion of underlying pancreatic disease that may require
speciﬁc intervention. Oral pancreatic enzyme replace-
ment to correct maldigestion, particularly of fat, is necessary
to optimize incretin secretion and enable the absorption of
vitamin D and other fat-soluble vitamins. Insulin therapy is
ultimately needed for most patients, and metformin should
be considered when concomitant insulin resistance is pre-
sent. Since metformin may reduce the risk of pancreatic
cancer in patients with T2DM, its use is strongly encouraged
when evidence of insulin resistance is present (34).
Inaccurate classiﬁcation of diabetes in clinical prac-
tice has limited our understanding of the prevalence of
T3cDM, and even our current diagnostic criteria still re-
quire prospective validation before we can appreciate their
limitations as well as the health consequences of mis-
diagnosis. Most importantly, randomized clinical trial
evidence is needed for speciﬁed interventions to prevent
diabetes from developing in patients with pancreatic
disease and how to best treat T3cDM in those affected.
Table 1—Clinical and laboratory ﬁndings in types of diabetes
Parameter T1DM T2DM T3cDM
Ketoacidosis Common Rare Rare
Hypoglycemia Common Rare Common
Peripheral insulin sensitivity Normal or decreased Decreased Normal or increased
Hepatic insulin sensitivity Normal or decreased Decreased Normal or decreased
Insulin levels Low or absent High or “normal” “Normal” or low
Glucagon levels Normal or high Normal or high “Normal” or low
PP levels Normal or low (late) Normal or high Low or absent
GIP levels Normal or low Variable Low
GLP-1 levels Normal Variable Variable
Typical age of onset Childhood or adolescence Adulthood Any
Typical etiology Autoimmune Obesity, age CP, cystic ﬁbrosis, postoperative
“Normal,” inappropriate in the context of elevated glucose. Adapted from Cui and Andersen (47).
Figure 2—Prevalence of types of diabetes. Distribution of types of diabetes (A) and causes of T3cDM (pancreatogenic) diabetes (B) based
on studies of 1,922 patients with diabetes reported by Hardt et al. (49). Reproduced from Cui and Andersen (47).
diabetes.diabetesjournals.org Andersen and Associates 1107
MECHANISMS OF DIABETES IN PANCREATIC
CANCER
The prevalence of diabetes among patients with PDAC
is extraordinarily high. In a study of 512 PDAC patients
and 933 control subjects, diabetes was found in 47% of
PDAC patients compared with only 7% of control subjects,
and although a normal fasting glucose was present in 59%
of control subjects, it was found in only 14% of PDAC pa-
tients (3) (Fig. 3). In 74% of the PDAC patients with dia-
betes, the diagnosis of diabetes was made within 24
months before the diagnosis of PDAC, frequently at a
time when the tumor was radiographically occult (40).
This suggests that in many patients, new-onset diabetes
is caused by the tumor and may be a useful “biomarker”
for the diagnosis of PDAC. The following observations
support this concept.
Despite the fact that canonical risk factors for diabetes
such as age, obesity, and a family history of diabetes are
also risk factors for PDAC, the incidence of diabetes in
PDAC is much higher than the incidence of diabetes among
other common malignancies. In a study of the prevalence
of diabetes among patients with the most common solid
tumors, diabetes was found in 68% of patients with PDAC
compared with 14.8–23.5% of patients with breast, colon,
lung, and prostate carcinoma and in age-matched control
subjects (1). Further, although insulin resistance is a
common ﬁnding in patients with both PDAC and diabe-
tes, most patients with PDAC report weight loss rather
than weight gain. The clinical features of deteriorating
glycemic control in conjunction with weight loss that
accompanies PDAC prior to its diagnosis are atypical
for T2DM; this combination of features should alert
the clinician to the possibility of PDAC-associated
diabetes.
Perhaps most compelling are the data showing that
new-onset diabetes associated with PDAC may resolve
following tumor resection, as long as there are sufﬁcient
islets left in the residual pancreatic tissue. Pancreatic
resection is a recognized cause of T3cDM, due to loss of
islet mass, and is seen in about half of all subjects after
proximal pancreatectomy. Earlier reports had observed an
actual improvement in diabetes after resection of some
pancreatic cancers (41), but it was unclear whether this
was a consequence of nutritional or other factors. In a
study of 104 patients who underwent PDAC resection, of
whom 41 had diabetes at the time of surgery, it was found
that 57% of the patients with new-onset diabetes had
resolution of their diabetes postoperatively, whereas all
of the patients with long-standing diabetes had a persis-
tence of diabetes after pancreatic resection (3) (Fig. 4).
These observations strongly suggest that new-onset dia-
betes associated with PDAC may be a paraneoplastic phe-
nomenon, where one or more factors induced by the
malignancy interfere with insulin secretion or insulin
action, leading to diabetes.
Numerous studies have attempted to identify the
mechanism(s) or the genomic and/or protein markers
of the diabetes caused by PDAC. Connexin 26, a gap
junction protein, has been described as being highly
overexpressed in islets of PDAC patients with diabetes
(42), and a PDAC-derived S-100A8 N-terminal peptide
has been described as a diabetogenic agent by Basso
et al. (43). Huang et al. (44) described two upregulated
genes in 27 patients with PDAC associated with new-
onset diabetes, vanin-1 and matrix metalloproteinase 9,
and a variety of microRNA fragments have been sug-
gested as possibly having predictive usefulness (45).
Chari and colleagues (46) at the Mayo Clinic have suggested
Figure 3—Prevalence of diabetes (DM) in PDAC. The prevalence of
diabetes and impaired fasting glucose in 512 pancreatic cancer
patients and 933 control subjects. Reproduced from Pannala
et al. (3).
Table 2—Diagnostic criteria for T3cDM
Major criteria (all must be fulﬁlled)
Presence of exocrine pancreatic insufﬁciency (according to monoclonal fecal elastase 1 or direct function tests).
Pathological pancreatic imaging (by endoscopic ultrasound, MRI, or computed tomography).
Absence of T1DM-associated autoimmune markers.
Minor criteria
Impaired b-cell function (e.g., as measured by HOMA-B, C-peptide/glucose ratio).
No excessive insulin resistance (e.g., as measured by HOMA of insulin resistance).
Impaired incretin (e.g., GIP) or PP secretion.
Low serum levels of lipid soluble vitamins (A, D, E, or K).
Adapted from Ewald and Bretzel (38). HOMA-B, HOMA of b-cell function.
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that adrenomedullin, carried within PDAC-derived exo-
somes, acts as a peptide mediator of the impaired insulin
sensitivity and secretion seen in PDAC-associated diabe-
tes. Adrenomedullin is a multifunctional vasoactive pep-
tide that has been implicated in inﬂammation and sepsis
and is highly overexpressed in PDAC (46). Together with
vanin-1, which is also expressed in response to inﬂam-
mation, these ﬁndings suggest that mediators of inﬂam-
mation may play a role in altered islet function and
insulin action in PDAC.
A deﬁciency of PP release has been documented in
T3cDM associated with pancreatic resection, CP, and
cystic ﬁbrosis (47), and a recent pilot study suggested
that impaired PP release may be a marker of PDAC-
associated diabetes (48). PP release is increased in T2DM,
and a deﬁcient PP response to nutrient ingestion may
differentiate new-onset diabetes that is caused by pancre-
atic exocrine disease from T2DM. In the pilot study by
Hart et al. (48), basal and meal-stimulated PP release was
signiﬁcantly decreased in patients with diabetes associ-
ated with PDAC localized to the head of the pancreas
compared with patients with T2DM. Further studies
sponsored by the National Institutes of Health–sponsored
Chronic Pancreatitis, Diabetes, Pancreatic Cancer consor-
tium are currently under way to determine whether a
deﬁcient PP response to nutrients can identify a high-
risk group with new-onset diabetes that includes patients
with early-stage PDAC.
CONCLUSIONS
Long-standing T2DM and CP (that may be associated with
T3cDM) are risk factors for the development of PDAC.
Obesity accompanying T2DM may also increase the risk of
PDAC due to hyperinsulinemia, the actions of adipokines,
or other factors. PDAC is also a cause of diabetes due to as
yet unknown mechanism(s), and the differentiation of
new-onset diabetes caused by PDAC, which is distinct
from long-standing T2DM or T3cDM associated with
CP, may allow for the diagnosis and intervention in
early-stage disease at a point at which curative therapy
is possible. Much information needs to be acquired,
however, to understand the mechanisms of both the
contributions of long-standing T2DM and obesity on
the development of PDAC and the cause of PDAC-
associated diabetes. The ability to distinguish PDAC-
associated diabetes from T2DM is critical for recognition
that new-onset diabetes in patients aged 50 years or older
may be a harbinger of PDAC leading to earlier PDAC de-
tection and improved therapeutic outcome in this deadly
malignancy.
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